Dr Elizabeth Salisbury-Afshar joins Ethics Talk to discuss her article, coauthored with Drs Catherine J. Livingston and Ricky N. Bluthenthal: “How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?”
The morbidity and mortality conference serves an important educational role for physicians and underscores the importance of error disclosure in improving patient safety.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
Two physicians offer commentary on the ethical issues that arise from medical students performing an invasive procedure on the newly dead as part of their medical training.
Two physicians offer commentary on the ethical issues that arise from medical students performing an invasive procedure on the newly dead as part of their medical training.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.
Medical students who are aware of information regarding a patient's prognosis are not at liberty to share the information with the patient, even if asked directly.